Jacobs (NYSE: JEC) has been selected to provide construction management services for global biologics leader, WuXi Biologics, to support the development of its new biologics drug substance manufacturing facility located in Dundalk, Co. Louth, Ireland. The 26-hectare $394m biomanufacturing facility, WuXi's first outside of China, will incorporate traditional fed-batch or perfusion process and continuous bioprocessing, a next-generation processing technology using selected single-use cell culture and fixed stainless-steel elements for purification. When completed, a total capacity of 48,000L fed-batch and 6,000L perfusion will be installed, representing one of the world's largest plants using single-use bioreactors. Source: Jacobs Press release 21/5/2019